Literature DB >> 3790922

Morbidity, mortality and local recurrence following regional node dissection for melanoma.

W G Bowsher, B A Taylor, L E Hughes.   

Abstract

Eighty-six patients who underwent regional node dissection (RND) for melanoma were reviewed with respect to short and long term postoperative morbidity, mortality and local recurrence rate. Twenty-eight per cent of dissections were prophylactic and seventy-two per cent therapeutic. There were significant wound related complications which tended to delay hospital discharge, in particular following axillary and groin dissections, but symptomatic long term complications were infrequent. The postoperative mortality rate was 1.2 per cent. Local recurrence in RND scars was particularly common in the neck (33 per cent). RND for melanoma is a safe procedure, with significant short term but relatively little long term morbidity. Both recurrence and morbidity should be borne in mind when considering patients for prophylactic RND. Surgeons should be prepared to use axial or myocutaneous flaps where extensive skin resection is necessary. A controlled trial of prophylactic antibiotics would be useful to try to reduce the incidence of wound infection.

Entities:  

Mesh:

Year:  1986        PMID: 3790922     DOI: 10.1002/bjs.1800731119

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

2.  The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients.

Authors:  Rachel K Voss; Kate D Cromwell; Yi-Ju Chiang; Jane M Armer; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Bob R Stewart; Simona F Shaitelman; Janice N Cormier
Journal:  J Surg Oncol       Date:  2015-10-18       Impact factor: 3.454

Review 3.  Recent progress in the treatment and prevention of cancer-related lymphedema.

Authors:  Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier
Journal:  CA Cancer J Clin       Date:  2014-11-19       Impact factor: 508.702

4.  The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

Authors:  Hasan H Danish; Kirtesh R Patel; Jeffrey M Switchenko; Theresa W Gillespie; Jaymin Jhaveri; Mudit Chowdhary; Mustafa Abugideiri; Keith A Delman; David H Lawson; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-12       Impact factor: 3.599

5.  Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma.

Authors:  Carlos Conill; Izaskun Valduvieco; Josep Domingo-Domènech; Pedro Arguis; Sergi Vidal-Sicart; Antonio Vilalta
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

6.  Retrospective trial of complete decongestive physical therapy for lower extremity secondary lymphedema in melanoma patients.

Authors:  Eli Carmeli; Roberto Bartoletti
Journal:  Support Care Cancer       Date:  2010-01-12       Impact factor: 3.603

7.  Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma.

Authors:  John R Hyngstrom; Yi-Ju Chiang; Kate D Cromwell; Merrick I Ross; Yan Xing; Kristi S Mungovan; Jeffrey E Lee; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jane M Armer; Janice N Cormier
Journal:  Melanoma Res       Date:  2013-08       Impact factor: 3.599

8.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

9.  Adjuvant radiation therapy in metastatic lymph nodes from melanoma.

Authors:  Jean-Emmanuel Bibault; Sylvain Dewas; Xavier Mirabel; Laurent Mortier; Nicolas Penel; Luc Vanseymortier; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-02-06       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.